Condition: NSCLC Stage IV · Sex Disorder · Hypogonadism, Male · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Although many phase III clinical trials evaluate the quality of life as a secondary endpoint, male sexuality remains a neglected topic in oncology research. In light of the long-term efficacy of new-generation anticancer treatments for ANSCLC (i.e. targeted therapies and immunotherapy), there is a paucity of data about any detrimental effect on fertility and sexuality that could complicate the therapy proposal, especially in young patients. The aim of this trial is to assess incidence of endocrine toxicity and sexual dysfuction in male patients receiving active treatment for ANSCLC
This description comes directly from the study's public registry record.
Emilio Bria, MD · 0630156318 · emilio.bria@policlinicogemelli.it
Emanuele Vita, MD · 0630156318 · dr.emanuele.vita@gmail.com
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Gemelli IRCCS | Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06532149